Table 1.
Demographic data
| Variables | Number (%) or Mean (SD) | CN (n = 195) | MCI (n = 65) |
|---|---|---|---|
| Age, y | 72.30 (6.31) | 71.69 (6.39) | 74.11 (5.75) |
| Education, y | 11.10 (4.78) | 11.37 (4.82) | 10.28 (4.60) |
| Sex (Female/Male) | 145/115 (55.8/44.2) | 99/96 (50.8/49.2) | 46/16 (70.8/29.2) |
| VRS | 17.82 (15.87) | 17.78 (15.88) | 17.95 (15.95) |
| APOE4 carriers (−/+) | 199/61 (76.5/23.5) | 160/35 (82.1/17.9) | 39/26 (60.0/40.0) |
| MMSE | 25.54 (3.39) | 26.64 (2.57) | 22.23 (3.42) |
| CERAD total score | 72.41 (15.48) | 78.52 (11.26) | 54.08 (11.39) |
| LTPAQ score, MET*hour/week | |||
| Midlife | 123.63 (97.43) | 131.93 (93.99) | 98.72 (103.89) |
| Late-life | 83.68 (84.54) | 89.80 (85.53) | 65.30 (79.31) |
| Cognitive activity score | 2.34 (0.68) | 2.41 (0.68) | 2.11 (0.63) |
| Aβ retention, SUVR | 1.31 (0.38) | 1.21 (0.26) | 1.63 (0.49) |
| Aβ positivity (−/+) | 186/74 (71.5/28.5) | 161/34 (82.6/17.4) | 25/40 (38.5/61.5) |
| AD-CM, SUVR | 1.38 (0.13) | 1.41 (0.12) | 1.31 (0.16) |
| AD-CT, mm | 2.39 (0.18) | 2.43 (0.15) | 2.28 (0.21) |
SD, standard deviation; CN, cognitive normal; MCI, mild cognitive impairment; VRS, vascular risk score; APOE4, apolipoprotein E ε4; MMSE, Mini-Mental Status Examination; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; LTPAQ, lifetime total physical activity questionnaire; MET, metabolic equivalent; Aβ, amyloid-β; SUVR, standardized uptake value ratio; AD-CM, Alzheimer’s disease signature region cerebral glucose metabolism; AD-CT, Alzheimer’s disease signature cortical thickness.